UNSPSC 51314315: Aspirin/chlorpheniramine/dextromethorphan/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE506. This VA Drug Class (RE506) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC.

UNSPSC 51314315 Aspirin/chlorpheniramine/dextromethorphan/phenylephrine is a Commodity code that describes combination cold and allergy relief formulations, but recent state and local solicitations tagged under this code show significant scope divergence — the opportunities posted involve naloxone and drug deactivation systems, therapeutic pharmacy initiatives, and broad generic pharmaceutical and OTC product supply agreements that extend well beyond the specific fixed-combination product named in the code. State and local health agencies, purchasing alliances, and county health departments are the primary buyers soliciting under this code. The work ranges from direct procurement of emergency-response medications (naloxone kits) and drug disposal systems for community health buildings, to strategic requests for information about direct-to-manufacturer pharmacy benefit programs, to cooperative purchasing agreements for multi-source generic pharmaceuticals and OTC products distributed across participating jurisdictions. The mismatch between the code's nominal scope and the actual procurement activity suggests either misclassification by issuing bodies or that the code is being used as a catch-all for pharmaceutical and medication-related procurements that do not fit narrower codes.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, requiring electronic bid submission and including drug-free workplace and E-Verify compliance. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescriptions program, explicitly seeking vendor experience with self-insured employers and flexible pricing models outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026 (response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with pricing weighted at 75 percent of evaluation and requirements for cGMP certification, DSCSA compliance, and relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson). No recent opportunities of clear relevance to the aspirin/chlorpheniramine/dextromethorphan/phenylephrine fixed-combination product itself appear in the posted solicitations.